Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.59 |
| ▸ | LCK | P06239 | 3/20 | 0.59 |
| ▸ | KIT | P10721 | 3/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214290 | 0.88 | MAPK14 (0.54) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL2216634 | 0.78 | MAPK14 (0.49) | MAPK14MAPK13MAPK11CYP3A4 | |
| SCHEMBL2216168 | 0.75 | MAPK14 (0.66) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL2217584 | 0.73 | MAPK14 (0.64) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL16576339 | 0.70 | MAPK14 (0.63) | MAPK14LCKKITKDRMAPK13 | |
| SCHEMBL1417097 | 0.69 | MAPK14 (0.59) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL12000896 | 0.68 | MAPK14 (0.80) | MAPK14LCKKIT | |
| SCHEMBL3638251 | 0.66 | MAPK14 (1.00) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL3669180 | 0.66 | MAPK14 (1.00) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1886401 | 0.66 | MAPK14 (0.83) | MAPK14LCKKITKDRMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 14/4885LCK 94/4885KIT 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.